Literature DB >> 8942831

Myocardial infarction in users of low-dose oral contraceptives.

S Sidney1, D B Petitti, C P Quesenberry, A L Klatsky, H K Ziel, S Wolf.   

Abstract

OBJECTIVE: To determine the relationship between the use of low-dose (less than 50 micrograms estrogen) oral contraceptives (OC) and myocardial infarction.
METHODS: In this population-based case-control study, all incident myocardial infarctions in women, ages 15-44 years who were members of the Kaiser Permanente Medical Care Program, Northern and Southern California regions were ascertained during a 39-month period from 1991 through 1994. For each woman with myocardial infarction, up to three age- and facility-matched controls were chosen at random from female members. Information about OC use (predominantly low-dose preparations) was obtained in face-to-face interviews.
RESULTS: There were 187 incident cases of myocardial infarction during 3.6 million woman-years of observation (incidence rate, 5.2 per 100,000 woman-years). The prevalence of several risk factors for myocardial infarction was lower in controls who were current users of OCs than in controls who were noncurrent (past and never) users. The odds ratio for myocardial infarction in current OC users compared with noncurrent users was 1.65 (95% confidence interval 0.45, 6.06) after adjustment for major risk factors and for race and ethnicity, corresponding to an excess risk of less than one case per 100,000 woman-years. The study had 80% power to detect a relative risk of 2.3 (one-sided test, alpha = .05). The odds ratio of myocardial infarction in past OC users was not elevated.
CONCLUSION: With respect to myocardial infarction, low-dose oral contraceptives can be used safely by women who lack risk factors for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8942831     DOI: 10.1016/s0029-7844(96)00351-1

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  10 in total

Review 1.  Benefits and risks of third-generation oral contraceptives.

Authors:  E S Leblanc; A Laws
Journal:  J Gen Intern Med       Date:  1999-10       Impact factor: 5.128

Review 2.  Cardiovascular events associated with different combined oral contraceptives: a review of current data.

Authors:  P Hannaford
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 3.  Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives.

Authors:  P C Hannaford; V Owen-Smith
Journal:  BMJ       Date:  1998-03-28

4.  Combined oral contraceptives, smoking, and cardiovascular risk.

Authors:  T M Farley; O Meirik; C L Chang; N R Poulter
Journal:  J Epidemiol Community Health       Date:  1998-12       Impact factor: 3.710

5.  Oral contraceptives and myocardial infarction: results of the MICA case-control study.

Authors:  N Dunn; M Thorogood; B Faragher; L de Caestecker; T M MacDonald; C McCollum; S Thomas; R Mann
Journal:  BMJ       Date:  1999-06-12

6.  Risk of myocardial infarction in young female smokers.

Authors:  N R Dunn; B Faragher; M Thorogood; L de Caestecker; T M MacDonald; C McCollum; S Thomas; R Mann
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

Review 7.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

8.  Four decades of research on hormonal contraception.

Authors:  Diana B Petitti; Stephen Sidney
Journal:  Perm J       Date:  2005

9.  Association between duration of oral contraceptive use and risk of hypertension: A meta-analysis.

Authors:  Hui Liu; Jie Yao; Weijing Wang; Dongfeng Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-06-13       Impact factor: 3.738

Review 10.  Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke.

Authors:  Rachel E J Roach; Frans M Helmerhorst; Willem M Lijfering; Theo Stijnen; Ale Algra; Olaf M Dekkers
Journal:  Cochrane Database Syst Rev       Date:  2015-08-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.